Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients

Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis

The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment.

Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.

Inclusion Criteria:

• aged 36 -72 years;
• Previously diagnosed with endometrial carcinoma;
• Histological Type of the tumor;
• Myometrial Invasion;
• lymph Node Invasion;
• Cervical Invasion;
• Biomarkers expression.

Exclusion Criteria:

• Lack of tumor tissue in tissue block